Harvey A K, Yu X P, Frolik C A, Chandrasekhar S
Endocrine Division, DC 0403, Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285, USA.
J Biol Chem. 1999 Aug 13;274(33):23249-55. doi: 10.1074/jbc.274.33.23249.
During endochondral bone formation, the growth plate chondrocytes proliferate, become hypertrophic, lose the cartilage phenotype, undergo mineralization, and provide a scaffold upon which subsequent longitudinal bone growth occurs. Parathyroid hormone (PTH), a calcium-regulating hormone, and parathyroid hormone-related peptide (PTHrP), which shares several properties with PTH, have profound effects on skeletal growth and new bone formation. In order to define further the mechanism by which PTH/PTHrP promotes the cartilage phenotype, chondrocytes isolated from the rib cages of developing rat embryos were evaluated for the biosynthesis of aggrecan. Cells treated with PTH-(1-34) for a 4-h period followed by a 20-h recovery period showed a significant increase in cartilage proteoglycan (aggrecan) synthesis in a dose-dependent manner. Only N-terminally intact PTH and PTHrP were effective in stimulating aggrecan synthesis. Addition of a neutralizing antibody to insulin-like growth factor-I (IGF-I) during PTH treatment resulted in the inhibition of PTH-stimulated aggrecan synthesis, whereas the addition of a neutralizing antibody to insulin-like growth factor-binding protein-2 (IGFBP-2) resulted in an increase in synthesis in both the control and PTH-treated cells. In addition, PTH treatment resulted in an increase in the mRNA for aggrecan, a reduction in IGFBP-3 mRNA, and no discernible changes in IGF-I mRNA levels, which was complemented by quantitative changes in IGFBP-3 and free IGF-I levels. The reciprocal relationship in the expression of aggrecan and IGFBP was further confirmed in chondrocytes from various gestational stages during normal development. Collectively, our results indicate that the effect of PTH may be mediated at least in part through the regulation of the IGF/IGFBP axis, by a decrease in the level of IGFBP-3, and an increase in free IGF-I levels. It is likely that the local increase in IGF-I may lead to an increase in cartilage type proteoglycan synthesis and maintenance of the cartilage phenotype. The consequence of the prolonged maintenance may be to halt mineralization while a new scaffolding is created.
在软骨内骨形成过程中,生长板软骨细胞增殖、肥大、失去软骨表型、发生矿化,并提供一个支架,随后的纵向骨生长在此支架上发生。甲状旁腺激素(PTH)是一种钙调节激素,甲状旁腺激素相关肽(PTHrP)与PTH具有若干共同特性,对骨骼生长和新骨形成有深远影响。为了进一步确定PTH/PTHrP促进软骨表型的机制,对从发育中的大鼠胚胎胸廓分离的软骨细胞进行了聚集蛋白聚糖生物合成评估。用PTH-(1-34)处理细胞4小时,随后恢复期20小时,结果显示软骨蛋白聚糖(聚集蛋白聚糖)合成呈剂量依赖性显著增加。只有N端完整的PTH和PTHrP能有效刺激聚集蛋白聚糖合成。在PTH处理期间添加胰岛素样生长因子-I(IGF-I)的中和抗体导致PTH刺激的聚集蛋白聚糖合成受到抑制,而添加胰岛素样生长因子结合蛋白-2(IGFBP-2)的中和抗体导致对照细胞和PTH处理细胞的合成均增加。此外,PTH处理导致聚集蛋白聚糖mRNA增加,IGFBP-3 mRNA减少,IGF-I mRNA水平无明显变化,IGFBP-3和游离IGF-I水平的定量变化与之相符。聚集蛋白聚糖和IGFBP表达的这种相互关系在正常发育过程中不同妊娠阶段的软骨细胞中得到进一步证实。总体而言,我们的结果表明,PTH的作用可能至少部分通过调节IGF/IGFBP轴介导,即通过降低IGFBP-3水平和增加游离IGF-I水平。局部IGF-I的增加可能导致软骨型蛋白聚糖合成增加和软骨表型的维持。这种延长维持的结果可能是在形成新的支架时停止矿化。